Dove Medical Press podcasts

This week's guest on the Medical Insider COPD podcast is Professor Eric Bateman, a Chest Physician and Professor of Respiratory Medicine at the University of Cape Town, South Africa. Join him and Dr Richard Russell as they discuss the barriers impeding implementation of global COPD recommendations in low- and middle-income countries (LMICs) and how global guidelines might better cater to LMICs,1,2 highlighting the importance of treatment accessibility worldwide. 1,3 Dr Russell will then present important takeaways from a new and exciting publication on the use of diaphragmatic movement as a prognostic marker of COPD. 4 This will be followed by a dive into social media, where patients with COPD are discussing the safety of resuming travelling. Don’t miss out on this exciting episode of the Medical Insider COPD and remember to subscribe!
1. Hurst JR, et al. Ann Am Thorac Soc 2021;18:1269–1277;2. Global Initiative for Chronic Obstructive Lung Disease. 2022 Update. Available at: here . Last accessed: July 2022;3. Brakema EA, et al. NPJ Prim Care Respir Med 2019;29:6; 4. Mekov E, et al. Int J Chron Obstruct Pulmon Dis 2022;17:1041–1050.
Disclosures Professor Eric Bateman Eric Bateman has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Hikma Pharma, Menarini, Novartis, Regeneron and Sanofi Genzyme. He also reports consulting fees from AstraZeneca, Novartis, Regeneron and Sanofi Genzyme in the past 3 years.
Bios:
Professor Eric Bateman Professor Eric Bateman is the founder and former director of the University of Cape Town Lung Institute and former Head of the Division of Pulmonology at the University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. His primary research interests include the pharmacology and management of asthma and COPD, as well as community-based interventions to improve the care of patients. He has published more than 370 papers in international peer-reviewed journals. He is a member of both the Board and the Science Committee of the Global Initiative for Asthma and has served as President of the South African Thoracic Society. He has received numerous awards including the President’s Award from the European Thoracic Society for his global contribution to Respiratory Medicine (2012), South Africa’s National Science and Technology Forum BHP-Billiton Lifetime Award for Outstanding Contribution to Science, Engineering, Technology and Innovation (2014) and the World Lung Health Award from the American Thoracic Society (2018).
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

In this episode of the Medical Insider COPD podcast, Dr Richard Russell is joined by Professor Sinthia Bosnic-Anticevich to explore the importance of inspiratory effort in COPD. 1 They will discuss the different types of inhalers available, the impact of suboptimal inspiratory effort on the management of COPD and the key considerations for clinicians when prescribing an inhaler. 2–4 Dr Russell will also share highlights from a recent publication on dust allergen sensitisation, modifying home circumstances and the impact of these factors on exacerbations, 5 before sharing this week’s social media hot topic – fatigue in COPD. Subscribe now and join us again next time on the Medical Insider COPD!
1. Kocks J, et al. ERS 2021:OA81 (poster presentation);2. Ghosh S, et al. J Aerosol Med Pulm Drug Deliv 2017;30:381-387;3. Loh CH, et al. Ann Am Thorac Soc 2017;14:1305-1311;4. Usmani O. Ther Clin Risk Manag 2019;5:461-472;5. Putcha N, et al. Am J Respir Crit Care Med 2022;205:412-420.
Disclosures Professor Sinthia Bosnic-Anticevich Professor Sinthia Bosnic-Anticevich reports Advisory Board Consultancies and lecture honorarium from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Mylan, Sanofi and TEVA Pharmaceuticals.
Bios:
Professor Sinthia Bosnic-Anticevich Sinthia Bosnic-Anticevich is a Professor at Sydney Pharmacy School, University of Sydney, Australia, the Research Leader of the Quality Use of Respiratory Medicines Group and the Director of Development at the Woolcock Institute of Medical Research. Alongside this, she is a Specialist Respiratory Pharmacist at Woolcock Respiratory Clinic, Australia, and Associate Editor of several high impact international respiratory journals including European Respiratory Review and European Respiratory Society Monograph.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Richard Russell is joined by Professor Antonio Anzueto in this episode of the Medical Insider COPD podcast to talk about real-world evidence and the gaps it can fill in the world of COPD research. Listen as they compare the finding from randomised controlled trials with real-world data and discuss how guidelines can be implemented in clinical practice. 1-3 Dr Russell will also highlight a new and exciting publication on the role of blood eosinophils in the development of obstructive lung disease, 4 before delving into this week’s social media hot topic of COPD fatigue. Make sure to subscribe so you don’t miss out!
1. Quint JK, et al. Adv Ther 2021;38:2249–2270;2. Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2022;3. Halpin DMG, et al. Respir Res 2016;17:120;4. Park HY, et al. Eur Respir J 2021;58:2003823.
Disclosures Dr Antonio Anzueto Dr Anzueto reports consultancy and advisory board membership fees from AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva Pharma; he also reports research grants from GlaxoSmithKline. Dr Anzueto is a member of the ATS/ERS Task Force on COPD, is a member of the GOLD Scientific Committee and is a member of the Infectious Diseases Society of America/ATS Community-Acquired Pneumonia Guidelines Committee.
Bios:
Dr Antonio Anzueto Antonio R. Anzueto, MD, is a Professor of Pulmonary/Critical Care in the department of Medicine at the University of Texas Health, San Antonio. He is Chief in the Pulmonary Section, Audie L. Murphy Memorial Veterans’ Hospital Division in San Antonio, Texas, where he also serves as Medical Director of the Respiratory Therapy Department and Medical Director of the Pulmonary Function Laboratory. Dr Anzueto currently serves on the editorial board of the American Journal of Respiratory and Critical Care Medicine, the American College of Chest Physicians (CHEST) journal, the COPD journal and the Respiratory Research journal. He is affiliated with several professional organisations, including the European Respiratory Society (ERS), the American Thoracic Society (ATS) and Global Obstructive Lung Disease (GOLD) initiative.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

To begin this episode of the Medical Insider COPD podcast, Dr Richard Russell is joined by Professor James Chalmers once more to delve into the topic of bronchiectasis. Specifically, they will be discussing how patients with bronchiectasis compare with patients with COPD, what treatments are the most appropriate and what the guidelines recommend. 1–3 Dr Russell also presents a new publication looking into the impact of air pollution on the respiratory health of patients with COPD, 4 and highlights what patients have been talking about on social media this week, including vaccination and exercise programmes during the COVID-19 pandemic.
1. Chalmers JD, et al. Am J Respir Crit Care Med 2018;197:1410–1420;2. Polverino E, et al. Eur Respir J 2017;50:1700629;3. Polverino E, et al. Eur Respir J 2018;51:1800328;4. Evangelopoulos D, et al. Eur Respir J 2021;58:2003432.
Disclosures Professor James ChalmersProfessor James Chalmers has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis and Zambon. He has also received research grant support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Insmed and Novartis.
Bios:
Professor James ChalmersProfessor James Chalmers is the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and an Honorary consultant physician at Ninewells Hospital. His clinical and research interests are in difficult airways diseases, particularly bronchiectasis and COPD. He chaired the 2017 European Respiratory Society bronchiectasis guidelines, with 2020 Guidelines on inhaled corticosteroid use in COPD and the 2021 COVID-19 management guidelines. He is also deputy chief editor of the European Respiratory Journal.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

On the Medical Insider COPD Podcast this week, Dr Richard Russell is joined by Professor MeiLan Han from the University of Michigan in the United States. She will be discussing early COPD and how imaging can play a role in the diagnosis and management of COPD. 1-3 Listen as she explores the benefits of identifying COPD earlier in the course of the disease as well as in younger patients, 1,2 delving into her experience working on large long-term cohort studies. 4 Dr Russell will then present a new publication on the use of beta-blockers in patients with COPD following a myocardial infarction. 5 Stay to the end to hear Dr Russell’s thoughts on the ‘invisible epidemic’ of COPD and how we can increase awareness of the disease across the globe!
1 Labaki WW & Han MK. Ann Am Thorac Soc 2018;15:S243-S248;2 Han MK, et al. Am J Respir Crit Care Med 2020;203:414-423;3 Ash SY, et al. Radiology 2021;299:222-231;4 Lowe KE, et al. Chronic Obstrust Pulmon Dis 2019;6:384-399;5 Rasmussen DB, et al. Thorax 2020;75:928-933.
DisclosuresMeiLan Han reports personal fees from Aerogen, Altesa Biopharma, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, DevPro, GlaxoSmithKline, Integrity, Medscape, Merck, Mylan, Novartis, Polarian, Pulmonx, Regeneron, Sanofi, Teva, United Therapeutics, UpToDate and Verona. She has received either in kind research support or funds paid to the institution from AstraZeneca, Biodesix, Boehringer Ingelheim, Gala Therapeutics, NIH, Novartis, Nuvaira, Sanofi, Sunovion, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma
Bio:
Professor MeiLan HanMeiLan Han is a Professor of Internal Medicine and Chief of the Division of Pulmonary and Critical Care Medicine at the University of Michigan Health System. She belongs to numerous professional societies including the American Thoracic Society and the European Respiratory Society. She is also a Deputy Editor for the American Journal of Respiratory and Critical Care Medicine and serves as a member of the Global Obstructive Lung Disease (GOLD) scientific committee. She is also author of a book for the lay public, Breathing Lessons, a Doctor’s Guide to Lung Health.
 
This series of podcasts are intended for healthcare professionals only.The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

This episode’s guest on the Medical Insider COPD podcast is Dr Barbara Yawn, a primary care physician and COPD clinical researcher. Join her and Dr Richard Russell as they explore the impact of breathlessness from the patient perspective, discussing physical activity, pharmacotherapy and mortality. 1-4 Dr Russell will then present the key takeaways from a new and exciting publication on the real-world impact of exacerbations on quality of life. 5 This is followed by a dive into the world of social media, where patients with COPD are discussing the use of face masks to prevent the transmission of respiratory viruses this winter.
1 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 20222 Hutchinson A, et al. Eur Respir J 2018;51:1701477;3 Waschki B, et al. Chest 2011;140:331-332;4 Watz H, et al. Eur Respir J 2014;44:1521;5 Stöber A, et al. Int J Chron Obstruct Pulmon Dis 2021;16:2637-2651
DisclosuresDr Yawn reports advisory board membership and consultancy fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Teva. She also reports research support for investigator-initiated research from GlaxoSmithKline.
Bio:
Dr Barbara YawnDr Barbara Yawn (MD MSc FAAFP) is Professor of Family and Community Health at the University of Minnesota, having retired as Director of Research at the Olmsted Medical Center and as Chief Science Officer of the COPD Foundation, USA. She is the Editor-in-Chief and Founding Editor of Respiratory Medicine Case Report Journal. Dr Yawn began her career in rural family medicine, moving on to found a research programme at the Olmsted Medical Center. She has served on numerous US national guideline panels. She has published over 400 peer-reviewed articles, several books and book chapters and is a frequent speaker at respiratory conferences in the US and internationally.
 
This series of podcasts are intended for healthcare professionals only.The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

In this episode of the Medical Insider COPD podcast, Dr Richard Russell is joined by Dr Brad Drummond to discuss the topic of inhaler adherence in COPD. They will explain the factors that affect device adherence, how we can improve adherence in our patients, and the impact adherence can have on COPD outcomes. 1,2 Dr Russell will also delve into a newly released publication on necroptosis and emphysema in patients with COPD,3 before discussing the importance of talking to your patients about COVID-19 vaccination. Don’t miss out!
1 Jardim JR & Nascimento OA. Med Sci 2019;7:54;2 Restrepo RD, et al. Int J Chron Obstruct Pulmon Dis 2008;3:371–384;3 Zhe L, et al. Am J Respir Crit Care Med 2021;204:667–681.
DisclosuresDr Brad DrummondDr Drummond received compensation from Boehringer Ingelheim for development and recording of the podcast. Unrelated to the podcast, he has the following disclosures: Consulting (last 36 months): American Society of Hospital Pharmacists, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Midmark, Polarean and Teva; Research grants from Boehringer Ingelheim (external collaborative project), US Department of Defense, National Institutes of Health and Teva.
Bios:
Dr Brad DrummondDr Brad Drummond is a board-certified Pulmonary and Critical Care Physician. He is also a clinical and translational researcher whose research focus includes characterising the mechanisms for development of chronic lung disease in individuals at risk of, or with, COPD. His primary projects include a US National Heart, Lung, and Blood Institute-funded study of the role of nasal mucosal immunity and microbiome on COPD disease control. Additionally, he is the Director of the University of North Carolina Obstructive Lung Diseases Clinical and Translational Research Center, where he oversees clinical research studies supported by the National Institutes of Health and industry sponsors.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Dr Marc Miravitlles is back to discuss mortality analyses with Dr Richard Russell.1 They will review what the guidelines recommend for initial and follow-up treatment of COPD, who should receive inhaled corticosteroids and how we should interpret mortality analyses in the COPD field.2–4 Dr Russell will then dive into a new publication on the use of FEV3/FEV6 in early airways disease identification,5 before highlighting what’s hot on social media. This week, the focus is on Lacing Up for Lungs and promoting an active and healthy lifestyle. Don’t miss out!
1 Miravitlles M, et al. Am J Respir Crit Care Med 2021;203:A2251; 2 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;3 Chalmers JD, et al. Eur Respir J 2020;55:2000351;4 Suissa S & Ariel A. Eur Respir J 2018;52:1801848;5 Yee N, et al. Chest 2021; doi: 10.1016/j.chest.2021.10.046
DisclosuresDr Marc Miravitlles has received speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Grifols, Menarini, Novartis, Rovi, Sandoz and Zambon. He reports consulting fees from AstraZeneca, Atriva Therapeutics, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Ferrer, Gebro Pharma, GlaxoSmithKline, Grifols, Inhibrx, Laboratorios Esteve, Mereo Biopharma, Novartis, ONO Pharma, Palobiofarma, pH Pharma, Sanofi, SL Spin Therapeutics, Takeda, and Verona Pharma, and research grants from Grifols.   
Bio:
Dr Marc MiravitllesDr Marc Miravitlles is a Senior Researcher and Consultant at Vall d’Hebron University Hospital, Barcelona, Spain. He was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and Guidelines Director of the ERS. He has acted as a consultant for the development of international guidelines on COPD, including the American Thoracic Society and ERS guidelines on exacerbations of COPD. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD and the coordinator of the Spanish National Guidelines for COPD
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

On this episode of the Medical Insider COPD podcast, Professor Jadwiga Wedzicha joins Dr Richard Russell to discuss the importance of early intervention in COPD.1 She will explore the use of optimised bronchodilation to improve early symptoms and physical activity,1,2 what the guidelines recommend when treating patients with milder disease,3 and how HCPs can start making a difference earlier.4 Dr Russell will then highlight the important takeaways from a 12-year follow-up study on mortality prediction in COPD,5 followed by a social media update on patients’ thoughts about the current COVID-19 pandemic. Don’t miss out on this exciting episode of the Medical Insider COPD podcast!
1 Buhl R, et al. Adv Ther 2020;37:4175–4189;2 O’Donnell DE, et al. Adv Ther 2020;37:41–60;3 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;4 Zhou Y, et al. N Engl J Med 2017;377:923–935;5 Athlin A, et al. Int J Chron Obstruct Pulmon Dis 2021;16:665–675.
DisclosuresProfessor Wedzicha reports grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline and Novartis; she also reports meeting expenses from AstraZeneca, Boehringer Ingelheim and Novartis, and honoraria for an advisory board from Gilead.
Bio:
Professor Jadwiga WedzichaJadwiga Wedzicha is Professor of Respiratory Medicine and Head of the Respiratory Division at the National Heart and Lung Institute, Imperial College London, and Honorary Consultant at Royal Brompton and Harefield Hospitals. She is a Fellow both of the American Thoracic Society and of the European Respiratory Society (ERS). Professor Wedzicha was Editor-in-Chief of Thorax from 2002 to 2010 and is currently Editor-in-Chief for the American Journal of Respiratory and Critical Care Medicine. She was the Lancet ombudsman until 2014, Publications Director for the ERS and has also previously been ERS Guidelines Director.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.

Join Dr Richard Russell and Professor Samy Suissa for the first episode of Season 4, as they discuss the importance of study design in the interpretation of COPD clinical trials.1,2 Listen as the experts examine the outcomes of well-known triple therapy studies and the consequences they may have for clinical practice.3,4 Dr Russell will also share highlights from a recent publication on the impact of best practice tariffs on COPD outcomes,5 before sharing this week’s social media hot topic of pulse oximeters and how patients can use them effectively.
1 Suissa S. COPD 2021;18:485–492; 2 Suissa S. COPD 2021; https://doi.org/10.1080/15412555.2021.1982886;3 Lipson DA, et al. N Engl J Med 2018;378:1671–1680; 4 Rabe KF, et al. N Engl J Med 2020;383:35–48; 5 Stone PW, et al. Thorax 2022;77:239–246.
DisclosuresProfessor Samy SuissaIn the last 3 years, Professor Suissa has attended scientific advisory committee meetings for Atara, Merck, Panalgo, Pfizer and Seqirus, and has received speaking fees from Boehringer Ingelheim and Novartis. Previously, he received research grants from Boehringer Ingelheim and Novartis.
Bios:
Professor Samy SuissaProfessor Suissa is a Distinguished James McGill Professor of Epidemiology and Biostatistics at McGill University, Canada, and Director of the Centre for Clinical Epidemiology, Lady Davis Institute of the Jewish General Hospital, Montreal, Canada. He heads the Canadian Network for Observational Drug Effect Studies. Professor Suissa has conducted extensive research on the real-world effects of medications for different chronic diseases, including asthma, COPD and idiopathic pulmonary fibrosis. He specialises in research methods, has authored over 550 peer-reviewed papers and serves on the editorial boards of various scientific journals. He is a fellow of the Royal Society of Canada and of the Canadian Academy of Health Science. He has received the Distinguished Investigator award from the Canadian Institutes of Health Research and the FC Donders Professorship award from University of Utrecht, Netherlands.
 
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.